Biogen to Acquire Apellis for $5.6 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Should l Buy APLS?
Source: NASDAQ.COM
- Acquisition Agreement: Biogen has entered into a definitive agreement to acquire all outstanding shares of Apellis Pharmaceuticals for $41.00 per share in cash, totaling approximately $5.6 billion, reflecting Biogen's strong confidence in Apellis's future growth potential.
- Additional Payment Structure: Apellis shareholders will receive a nontransferable CVR entitling them to two payments of $2 per share, contingent on meeting specific global net sales thresholds, which not only enhances shareholder potential returns but also incentivizes Apellis's performance.
- Earnings Outlook Improvement: The acquisition is expected to significantly boost Biogen's non-GAAP EPS starting in 2027, with a compounded annual growth rate enhancing the company's profitability through the end of the decade, indicating a positive outlook for Biogen's future financial performance.
- Positive Market Reaction: In pre-market trading on Nasdaq, Apellis shares surged 140.5% to $41.10, indicating a favorable market response to the acquisition, which may further strengthen Biogen's market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APLS
Wall Street analysts forecast APLS stock price to rise
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 17.090
Low
19.00
Averages
31.69
High
48.00
Current: 17.090
Low
19.00
Averages
31.69
High
48.00
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biogen Acquires Apellis to Strengthen Immunology Position
- Acquisition Details: Biogen has agreed to acquire Apellis for $41 per share in cash, valuing the deal at approximately $5.6 billion, which is expected to enhance Biogen's market position in immunology and rare diseases while providing immediate revenue.
- Expanded Drug Portfolio: The acquisition adds two commercial medicines, EMPAVELI and SYFOVRE, to Biogen's portfolio, with projected combined net sales of $689 million by 2025 and a mid-to-high teens growth rate through at least 2028, significantly improving the company's long-term growth outlook.
- Significant Clinical Outcomes: EMPAVELI is the only FDA-approved treatment for C3G, demonstrating a 68% reduction in proteinuria in the VALIANT study, while SYFOVRE has shown substantial reductions in GA lesion growth in the OAKS and DERBY studies, further solidifying Biogen's expansion in nephrology.
- Future Outlook and Employee Integration: Biogen expects to integrate a significant portion of Apellis employees post-transaction, with plans to close the deal in Q2 2026, further enhancing the company's capabilities in treating kidney diseases with the anticipated launch of Felzartamab.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages shareholders of Apellis and Centessa Pharmaceuticals plc (NASDAQ:CNTA) to understand their legal rights, as the latter's deal involves $38.00 per share in cash plus a contingent value right worth up to $9.00, aiming to ensure fair treatment for shareholders.
- Asset Sale Impact: Allbirds, Inc. (NASDAQ:BIRD) sold its intellectual property and other assets for $39 million, and Halper Sadeh LLC may seek increased compensation and additional disclosures for shareholders to ensure transaction transparency.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, committed to combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors in the past, highlighting its influence in protecting investor rights.
See More
Apellis Pharmaceuticals Acquired by Biogen for $5.6 Billion
- Acquisition Details: Apellis Pharmaceuticals has agreed to be acquired by Biogen for $41 per share, totaling $5.6 billion, with the deal expected to close in Q2 2026, reflecting Biogen's strong interest and confidence in the market.
- Shareholder Value Enhancement: The transaction offers Apellis shareholders $41 in cash per share, representing an 86% premium over its 90-day volume-weighted average stock price, while also providing a nontransferable contingent value right worth $2 per share tied to Syfovre's net sales, further enhancing investment appeal.
- Product Portfolio Expansion: The acquisition will add Apellis' Empaveli and Syfovre to Biogen's portfolio, which generated $689 million in revenue last year, expected to strengthen Biogen's competitive position in the ophthalmic drug market.
- Financial Outlook Improvement: Biogen plans to fund the acquisition through a mix of cash and debt, anticipating an increase in its non-GAAP diluted EPS in 2027 and a compounded annual growth rate through 2030, indicating a positive impact on its long-term financial health.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Announcement: Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, resulting in a 140% surge in Apellis' shares during Tuesday's pre-market trading, indicating strong market enthusiasm and a significant boost to Biogen's position in the rare disease treatment sector.
- Retail Sentiment: Following the acquisition news, retail sentiment around Apellis on Stocktwits trended bullish with high message volumes, reflecting investor optimism about the company's future prospects, which could further drive up its stock price.
- Business Expansion: This acquisition will enhance Biogen's rare disease treatment portfolio and accelerate its expansion into nephrology, signaling a strategic shift towards high-growth areas to capture increasing market demand.
- Investor Attention: As the acquisition progresses, market focus on Apellis has intensified, with investors likely to closely monitor the integration process and its impact on Biogen's overall performance, suggesting potential future stock price volatility.
See More
Biogen to Acquire Apellis for $5.6 Billion
- Acquisition Agreement: Biogen has entered into a definitive agreement to acquire all outstanding shares of Apellis Pharmaceuticals for $41.00 per share in cash, totaling approximately $5.6 billion, reflecting Biogen's strong confidence in Apellis's future growth potential.
- Additional Payment Structure: Apellis shareholders will receive a nontransferable CVR entitling them to two payments of $2 per share, contingent on meeting specific global net sales thresholds, which not only enhances shareholder potential returns but also incentivizes Apellis's performance.
- Earnings Outlook Improvement: The acquisition is expected to significantly boost Biogen's non-GAAP EPS starting in 2027, with a compounded annual growth rate enhancing the company's profitability through the end of the decade, indicating a positive outlook for Biogen's future financial performance.
- Positive Market Reaction: In pre-market trading on Nasdaq, Apellis shares surged 140.5% to $41.10, indicating a favorable market response to the acquisition, which may further strengthen Biogen's market position.
See More
Biogen Acquires Apellis to Strengthen Immunology Position
- Acquisition Details: Biogen has agreed to acquire Apellis for $41 per share in cash, valuing the deal at approximately $5.6 billion, which is expected to enhance Biogen's market position in immunology and rare diseases while providing immediate revenue.
- Expanded Drug Portfolio: The acquisition adds two commercial medicines, EMPAVELI and SYFOVRE, to Biogen's portfolio, with projected combined net sales of $689 million by 2025 and a mid-to-high teens growth rate through at least 2028, significantly improving the company's long-term growth outlook.
- Significant Clinical Outcomes: EMPAVELI is the only FDA-approved treatment for C3G, demonstrating a 68% reduction in proteinuria in the VALIANT study, while SYFOVRE has shown substantial reductions in GA lesion growth in the OAKS and DERBY studies, further solidifying Biogen's expansion in nephrology.
- Future Outlook and Employee Integration: Biogen expects to integrate a significant portion of Apellis employees post-transaction, with plans to close the deal in Q2 2026, further enhancing the company's capabilities in treating kidney diseases with the anticipated launch of Felzartamab.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages shareholders of Apellis and Centessa Pharmaceuticals plc (NASDAQ:CNTA) to understand their legal rights, as the latter's deal involves $38.00 per share in cash plus a contingent value right worth up to $9.00, aiming to ensure fair treatment for shareholders.
- Asset Sale Impact: Allbirds, Inc. (NASDAQ:BIRD) sold its intellectual property and other assets for $39 million, and Halper Sadeh LLC may seek increased compensation and additional disclosures for shareholders to ensure transaction transparency.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, committed to combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors in the past, highlighting its influence in protecting investor rights.
See More
Apellis Pharmaceuticals Acquired by Biogen for $5.6 Billion
- Acquisition Details: Apellis Pharmaceuticals has agreed to be acquired by Biogen for $41 per share, totaling $5.6 billion, with the deal expected to close in Q2 2026, reflecting Biogen's strong interest and confidence in the market.
- Shareholder Value Enhancement: The transaction offers Apellis shareholders $41 in cash per share, representing an 86% premium over its 90-day volume-weighted average stock price, while also providing a nontransferable contingent value right worth $2 per share tied to Syfovre's net sales, further enhancing investment appeal.
- Product Portfolio Expansion: The acquisition will add Apellis' Empaveli and Syfovre to Biogen's portfolio, which generated $689 million in revenue last year, expected to strengthen Biogen's competitive position in the ophthalmic drug market.
- Financial Outlook Improvement: Biogen plans to fund the acquisition through a mix of cash and debt, anticipating an increase in its non-GAAP diluted EPS in 2027 and a compounded annual growth rate through 2030, indicating a positive impact on its long-term financial health.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Announcement: Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, resulting in a 140% surge in Apellis' shares during Tuesday's pre-market trading, indicating strong market enthusiasm and a significant boost to Biogen's position in the rare disease treatment sector.
- Retail Sentiment: Following the acquisition news, retail sentiment around Apellis on Stocktwits trended bullish with high message volumes, reflecting investor optimism about the company's future prospects, which could further drive up its stock price.
- Business Expansion: This acquisition will enhance Biogen's rare disease treatment portfolio and accelerate its expansion into nephrology, signaling a strategic shift towards high-growth areas to capture increasing market demand.
- Investor Attention: As the acquisition progresses, market focus on Apellis has intensified, with investors likely to closely monitor the integration process and its impact on Biogen's overall performance, suggesting potential future stock price volatility.
See More
Biogen to Acquire Apellis for $5.6 Billion
- Acquisition Agreement: Biogen has entered into a definitive agreement to acquire all outstanding shares of Apellis Pharmaceuticals for $41.00 per share in cash, totaling approximately $5.6 billion, reflecting Biogen's strong confidence in Apellis's future growth potential.
- Additional Payment Structure: Apellis shareholders will receive a nontransferable CVR entitling them to two payments of $2 per share, contingent on meeting specific global net sales thresholds, which not only enhances shareholder potential returns but also incentivizes Apellis's performance.
- Earnings Outlook Improvement: The acquisition is expected to significantly boost Biogen's non-GAAP EPS starting in 2027, with a compounded annual growth rate enhancing the company's profitability through the end of the decade, indicating a positive outlook for Biogen's future financial performance.
- Positive Market Reaction: In pre-market trading on Nasdaq, Apellis shares surged 140.5% to $41.10, indicating a favorable market response to the acquisition, which may further strengthen Biogen's market position.
See More
